CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Technegas (Technetium Tc 99-m Labeled...
FDA Approves Rivfloza (nedosiran) for the Treatment of...
FDA Approves Exxua (gepirone) for the Treatment of...
FDA Approves Pombiliti (cipaglucosidase alfa-atga) +...
U.S. FDA Approves Subcutaneous Administration of...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.